Alzheimer’s Disease – Epidemiology – Middle East & Africa
- The number of prevalent cases of AD in the countries under study will increase by 43% over the 10-year forecast period, from 384,000 to 548,000.
- Of the countries considered in this analysis, Egypt has the highest prevalence of AD: 1.79 per 1,000.
- The average age of all prevalent cases of AD in the countries under study is 79.
- 59% of all prevalent cases of AD in the countries under study are female.
Table of contents
- Alzheimer's Disease - Epidemiology - Middle East & Africa
- Introduction
- Key Findings
- Total Prevalence of Alzheimer's Disease per 1,000 People Aged 30+ in 2020 and 2030
- Total Prevalence of Alzheimer's Disease per 1,000 People Aged 30+ in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Alzheimer's Disease Over the Next 10 Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Alzheimer's Disease Over the Next 10 Years
- Total Prevalent Cases of Alzheimer's Disease by Severity
- Total Prevalent Cases of Alzheimer's Disease by Severity
- Number of Additional Total Prevalent Cases of Alzheimer's Disease in 2030 in the Countries Under Study due to Trends in Risk or Survival
- Number of Additional Total Prevalent Cases of Alzheimer's Disease in 2030 in the Countries Under Study due to Trends in Risk or Survival
- Key Findings
- Epidemiology Data
- Methods
- Total Incident Cases of Asymptomatic Alzheimer's Disease
- Multistate Model of the Progression of Alzheimer's Disease
- Total Incident Cases of Mild Cognitive Impairment due to Alzheimer's Disease
- Total Incident Cases of Alzheimer's Disease
- Total Prevalent Cases of Asymptomatic Alzheimer's Disease
- Total Prevalent Cases of Mild Cognitive Impairment due to Alzheimer's Disease
- Total Prevalent Cases of Alzheimer's Disease
- Total Prevalent Cases of Alzheimer's Disease by APOE e4 Status
- Reference Materials
- Introduction
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.